Northern Trust Corp Invests $661,000 in Atyr PHARMA INC (NASDAQ:ATYR)

Northern Trust Corp acquired a new stake in shares of Atyr PHARMA INC (NASDAQ:ATYR - Free Report) in the fourth quarter, according to its most recent disclosure with the SEC. The firm acquired 182,625 shares of the company's stock, valued at approximately $661,000. Northern Trust Corp owned approximately 0.22% of Atyr PHARMA at the end of the most recent reporting period.

A number of other institutional investors have also added to or reduced their stakes in ATYR. Oxford Asset Management LLP bought a new position in shares of Atyr PHARMA during the 4th quarter valued at approximately $115,000. Boothbay Fund Management LLC bought a new position in shares of Atyr PHARMA during the 4th quarter valued at approximately $53,000. Adage Capital Partners GP L.L.C. bought a new position in shares of Atyr PHARMA during the 4th quarter valued at approximately $3,620,000. Alpine Global Management LLC bought a new position in shares of Atyr PHARMA during the 4th quarter valued at approximately $63,000. Finally, Tower Research Capital LLC TRC bought a new position in shares of Atyr PHARMA during the 4th quarter valued at approximately $119,000. 61.72% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of research analysts have recently commented on ATYR shares. HC Wainwright reiterated a "buy" rating and set a $35.00 target price on shares of Atyr PHARMA in a research report on Monday, May 19th. Leerink Partners started coverage on Atyr PHARMA in a research report on Tuesday, February 18th. They set an "outperform" rating and a $16.00 target price for the company. Finally, Leerink Partnrs upgraded Atyr PHARMA to a "strong-buy" rating in a research report on Tuesday, February 18th. Six analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Buy" and an average price target of $18.60.

Atyr PHARMA Trading Up 6.3%

ATYR traded up $0.28 during trading on Monday, reaching $4.75. The company had a trading volume of 2,461,524 shares, compared to its average volume of 954,895. The stock has a market cap of $422.77 million, a P/E ratio of -5.05 and a beta of 0.79. The business has a 50 day simple moving average of $3.28 and a 200-day simple moving average of $3.45. Atyr PHARMA INC has a 52 week low of $1.42 and a 52 week high of $4.83. The company has a quick ratio of 5.41, a current ratio of 5.41 and a debt-to-equity ratio of 0.02.

Atyr PHARMA (NASDAQ:ATYR - Get Free Report) last issued its quarterly earnings results on Wednesday, May 7th. The company reported ($0.17) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.19) by $0.02. On average, equities analysts anticipate that Atyr PHARMA INC will post -0.91 EPS for the current fiscal year.

About Atyr PHARMA

aTyr Pharma, Inc engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.